GNH USA

Europe — EMA

Normosang (Human Hemin)

GNH USA supplies Normosang (Human Hemin), a heme preparation indicated for acute intermittent porphyria attacks. Request a quote for worldwide supply.

Human Hemin

Request sourcing

1
Pack/s

What is Human Hemin?

Human Hemin, the active ingredient in Normosang, is a heme preparation presented as a lyophilized powder for intravenous use. It treats acute intermittent porphyria by supplying exogenous heme to patients experiencing acute attacks.

GNH USA supplies Normosang as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

What is Human Hemin used for?

Normosang is used in the management of acute intermittent porphyria, a disorder of heme biosynthesis. - Acute intermittent porphyria: Reduces accumulation of toxic porphyrin precursors during acute attacks. - Porphyria crises: Provides heme to alleviate severe neurovisceral symptoms. - Acute porphyria episodes: Helps restore normal heme feedback inhibition and stabilise metabolic pathways.

What are the side effects of Human Hemin?

Normosang may be associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Infusion site pain: Discomfort or burning at the injection site. - Headache: Mild to moderate headache during or after infusion. - Nausea: Transient nausea reported in some patients. - Fever: Low‑grade temperature elevation during treatment.

Serious or Rare Side Effects: - Hypotension: Sudden drop in blood pressure requiring monitoring. - Hemolysis: Breakdown of red blood cells, especially in patients with G6PD deficiency. - Severe allergic reaction: Anaphylaxis or angioedema necessitating immediate medical intervention.

What precautions apply to Human Hemin?

When using Normosang, clinicians should observe several safety measures. - Dose adjustment: Use caution in patients with hepatic impairment and monitor liver function tests. - Renal function: Monitor renal parameters in patients with pre‑existing kidney disease. - Pregnancy: Safety not established; weigh potential benefits against risks before use. - Concomitant drugs: Avoid simultaneous administration of other heme preparations to prevent overdose. - Store at 2‑8 °C: Keep refrigerated, protect from light, do not freeze or shake.

What does Human Hemin interact with?

Normosang can interact with other medicines, requiring careful assessment.

Major Interactions (Avoid): - Cytochrome P450 inducers: May reduce heme efficacy and precipitate breakthrough attacks. - Concurrent heme products: Increases risk of heme overload and related toxicity.

Moderate Interactions (Monitor Closely): - Iron supplements: May interfere with heme metabolism; monitor iron status. - Anticoagulants: Observe coagulation parameters as heme can affect platelet function. - Photosensitizing drugs: Enhanced photosensitivity may occur; advise patients on light protection.

Frequently asked questions

What is Normosang used for?+
Normosang is indicated for the treatment of acute intermittent porphyria. It provides exogenous heme during an acute attack, helping to suppress the overproduction of toxic porphyrin precursors and alleviate the severe neurovisceral symptoms associated with the condition.
How does Human Hemin work in the body?+
Human Hemin supplies external heme, which feeds back to inhibit aminolevulinic acid synthase, the first enzyme in the heme biosynthetic pathway. This feedback reduces the buildup of upstream porphyrin intermediates that cause the clinical manifestations of acute porphyria attacks.
What is the usual dose of Normosang?+
The dosage of Normosang is determined by the prescribing physician based on the severity of the porphyria attack, patient weight, and clinical response. The prescriber will calculate the appropriate amount and infusion rate for each individual case.
Is Normosang safe during pregnancy or breastfeeding?+
Safety data for Normosang in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by the treating physician.
How do I order Normosang from GNH USA?+
To order Normosang, submit an enquiry on the product page at gnh-usa.com specifying the required quantity. GNH USA supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain handling) and necessary import documentation.
How does Normosang compare with other porphyria treatments?+
Normosang is a heme preparation that directly replaces deficient heme, whereas alternative therapies may focus on symptom control or use different mechanisms such as enzyme inhibition. Compared with oral agents, intravenous Human Hemin provides rapid biochemical correction during acute attacks, making it the preferred option for severe episodes.
What are the storage and handling requirements for Normosang?+
Normosang should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. The lyophilized powder should be reconstituted with the supplied diluent immediately before intravenous infusion and used according to aseptic technique.
How is Normosang administered to patients?+
Normosang is supplied as a lyophilized powder for intravenous infusion. After reconstitution with the appropriate diluent, the solution is administered through a controlled IV infusion set, typically over a period defined by the prescriber, under close clinical monitoring.
What are the most serious risks associated with Normosang?+
The most serious risks include severe hypotension, hemolysis (especially in patients with G6PD deficiency), and anaphylactic reactions. Prompt recognition and management of these events are essential, and patients should be monitored closely during and after the infusion.
Who should not use Normosang?+
Normosang is contraindicated in patients with known hypersensitivity to Human Hemin or any component of the formulation. It should also be avoided in individuals with severe G6PD deficiency due to the risk of hemolysis, and in patients where alternative, safer therapies are available.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Human Hemin
Route
Intravenous Use
Manufacturer
Recordati Rare Diseases
Origin
EU

Related products

Human Hemin Orphan Europe

Human Hemin Orphan Europe

Human Hemin

Recordati Rare Diseases
EU
Normosang

Normosang

Human Hemin

Recordati Rare Diseases
EU
Normosang

Normosang

Human Hemin

Recordati Rare Diseases
EU
Normosang

Normosang

Human Hemin

Orphan Europe Sarl
EU